logo
Products
Services
Resources
Selection Guides
About
APC Anti-human CD22 Antibody
HIB22
HIB22 is an anti-human monoclonal antibody that recognizes the CD22 antigen. CD22 (also known as BL-CAM or Lyb8) is a 120 - 130 kD glycoprotein that is located on the surface of cells like B cells and stem cells. CD22 plays a role in essential cellular pathways, namely, the negative regulation of B cell receptor signaling pathway. Moreover, in many organisms, it is a negative regulator of calcium-mediated signaling, suppresses immunoglobulin secretion and is involved in the negative regulation of B cell receptor signaling pathway. From a research standpoint, it is of biological interest due to its association with key macromolecules/ligands like PI3-kinase, PLCg1, p53/56lyn and CD45. CD22 is a fairly uncommon antibody target, with a little more than 4000 publications in the last decade. Even still, CD22 is vital to cell biology research, frequently serving as a phenotypic marker for differentiating cell types in flow cytometric applications. This antibody was purified through affinity chromatography and conjugated to APC (ex/em = 651/660 nm). It is compatible with the 642 nm laser and 702/85 nm bandpass filter (for example, as in the Luminex Amnis FlowSight).
product image
product image
CatalogSize
Price
Quantity
102201C025 tests
Price
102201C1100 tests
Price
102201C2500 tests
Price
 
Antibody properties

Other namesBL-CAM, Siglec-2
CloneHIB22
HostMouse
IsotypeIgG1
ReactivityHuman
Spectral properties

Correction factor (280 nm)0.195
Extinction coefficient (cm -1 M -1)
730000
Excitation (nm)651
Emission (nm)660
Storage, safety and handling

H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on April 4, 2026